

RealRate

PHARMACEUTICAL 2019



Entasis Therapeutics Holdings Inc. Rank 52 of 363







PHARMACEUTICAL 2019





## Entasis Therapeutics Holdings Inc. Rank 52 of 363

The relative strengths and weaknesses of Entasis Therapeutics Holdings Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Entasis Therapeutics Holdings Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 87% points. The greatest weakness of Entasis Therapeutics Holdings Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 28% points.

The company's Economic Capital Ratio, given in the ranking table, is 229%, being 192% points above the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	88,792
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	6,216
Liabilities, Non-Current	0
Other Assets	63
Other Compr. Net Income	-9.0
Other Expenses	472
Other Liabilities	175
Other Net Income	0
Other Revenues	10,727
Property and Equipment	419
Research and Development	33,046
Selling, General and Administrative Expense	10,161

Output Variable	Value in 1000 USD
Assets	89,274
Liabilities	6,391
Expenses	43,679
Revenues	10,727
Stockholders Equity	82,883
Net Income	-32,952
Comprehensive Net Income	-32,956
Economic Capital Ratio	229%

